Summary Basis of Decision (SBD) for STIVARGA

Health Canada has issued a Notice of Compliance to Bayer Inc. for the drug product, Stivarga. Stivarga, a multikinase inhibitor and antineoplastic agent, was authorized for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-based chemotherapy, oxaliplatin, irinotecan, an anti-vascular endothelial growth factor (anti-VEGF) therapy, and, if KRAS wild type, an anti-epidermal growth factor receptor (anti-EGFR) therapy. Read more here.